CN1622819A - 一种抗风湿药物及其制备方法 - Google Patents
一种抗风湿药物及其制备方法 Download PDFInfo
- Publication number
- CN1622819A CN1622819A CNA028286421A CN02828642A CN1622819A CN 1622819 A CN1622819 A CN 1622819A CN A028286421 A CNA028286421 A CN A028286421A CN 02828642 A CN02828642 A CN 02828642A CN 1622819 A CN1622819 A CN 1622819A
- Authority
- CN
- China
- Prior art keywords
- microspheres
- rheumatism
- medicine
- medicament
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 118
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 230000000694 effects Effects 0.000 claims abstract description 91
- 241001197778 Tripterygium hypoglaucum Species 0.000 claims abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 24
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 9
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 42
- 229940079593 drug Drugs 0.000 claims description 41
- 239000000284 extract Substances 0.000 claims description 28
- 239000000843 powder Substances 0.000 claims description 28
- 239000002994 raw material Substances 0.000 claims description 26
- 239000000463 material Substances 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 18
- 240000007371 Cuscuta campestris Species 0.000 claims description 16
- 241000893536 Epimedium Species 0.000 claims description 16
- 235000018905 epimedium Nutrition 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 16
- 238000005520 cutting process Methods 0.000 claims description 14
- 238000002791 soaking Methods 0.000 claims description 14
- 239000003480 eluent Substances 0.000 claims description 13
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 claims description 13
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 claims description 13
- 239000011347 resin Substances 0.000 claims description 12
- 229920005989 resin Polymers 0.000 claims description 12
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 12
- 241000218993 Begonia Species 0.000 claims description 11
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 11
- 244000182216 Mimusops elengi Species 0.000 claims description 11
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 11
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 11
- 210000000582 semen Anatomy 0.000 claims description 11
- 239000003463 adsorbent Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 238000010298 pulverizing process Methods 0.000 claims description 9
- 239000003435 antirheumatic agent Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 7
- 235000015468 Lycium chinense Nutrition 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 235000013399 edible fruits Nutrition 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- IYCPMVXIUPYNHI-UHFFFAOYSA-N Icariside I Natural products C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 IYCPMVXIUPYNHI-UHFFFAOYSA-N 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- IYCPMVXIUPYNHI-WPKKLUCLSA-N 3,5-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 IYCPMVXIUPYNHI-WPKKLUCLSA-N 0.000 claims description 3
- 229930013930 alkaloid Chemical class 0.000 claims description 3
- 229930003944 flavone Natural products 0.000 claims description 3
- 235000011949 flavones Nutrition 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 231100000331 toxic Toxicity 0.000 claims description 3
- 230000002588 toxic effect Effects 0.000 claims description 3
- 150000003648 triterpenes Chemical class 0.000 claims description 3
- 230000005484 gravity Effects 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 238000003825 pressing Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 235000015463 Lycium carolinianum Nutrition 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 150000002213 flavones Chemical class 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 229940102223 injectable solution Drugs 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 150000003505 terpenes Chemical class 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 241001362421 Epimedium brevicornu Species 0.000 abstract description 2
- 244000013539 Cuscuta australis Species 0.000 abstract 1
- 241000110637 Cuscuta chinensis Species 0.000 abstract 1
- 239000006049 herbal material Substances 0.000 abstract 1
- 239000004005 microsphere Substances 0.000 description 150
- 241000700159 Rattus Species 0.000 description 67
- 241000699670 Mus sp. Species 0.000 description 59
- 241000699666 Mus <mouse, genus> Species 0.000 description 52
- 210000004027 cell Anatomy 0.000 description 36
- 239000002775 capsule Substances 0.000 description 26
- 208000009386 Experimental Arthritis Diseases 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 230000005764 inhibitory process Effects 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 230000008961 swelling Effects 0.000 description 21
- 239000002671 adjuvant Substances 0.000 description 20
- 206010070834 Sensitisation Diseases 0.000 description 17
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 17
- 230000008313 sensitization Effects 0.000 description 17
- 230000005951 type IV hypersensitivity Effects 0.000 description 17
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 17
- 239000006285 cell suspension Substances 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 15
- 210000000683 abdominal cavity Anatomy 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 108010006464 Hemolysin Proteins Proteins 0.000 description 10
- 239000003228 hemolysin Substances 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 10
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 9
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 102000000588 Interleukin-2 Human genes 0.000 description 9
- 230000002776 aggregation Effects 0.000 description 9
- 238000004220 aggregation Methods 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 229960004397 cyclophosphamide Drugs 0.000 description 9
- 239000002674 ointment Substances 0.000 description 9
- 239000002504 physiological saline solution Substances 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 210000002683 foot Anatomy 0.000 description 8
- 210000000548 hind-foot Anatomy 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 108010002352 Interleukin-1 Proteins 0.000 description 7
- 102000000589 Interleukin-1 Human genes 0.000 description 7
- 241000545405 Tripterygium Species 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 229930182470 glycoside Natural products 0.000 description 7
- 150000002338 glycosides Chemical class 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 210000000822 natural killer cell Anatomy 0.000 description 7
- 244000144730 Amygdalus persica Species 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 235000006040 Prunus persica var persica Nutrition 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 230000003356 anti-rheumatic effect Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 210000004988 splenocyte Anatomy 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 210000001541 thymus gland Anatomy 0.000 description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 5
- 229920001525 carrageenan Polymers 0.000 description 5
- 210000000845 cartilage Anatomy 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 229960003957 dexamethasone Drugs 0.000 description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000001503 joint Anatomy 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 208000008423 pleurisy Diseases 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 208000025747 Rheumatic disease Diseases 0.000 description 4
- 210000004100 adrenal gland Anatomy 0.000 description 4
- 210000000544 articulatio talocruralis Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 229940117173 croton oil Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000002437 synoviocyte Anatomy 0.000 description 4
- 108700031361 Brachyury Proteins 0.000 description 3
- 206010014025 Ear swelling Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 description 3
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 3
- 235000011613 Pinus brutia Nutrition 0.000 description 3
- 241000018646 Pinus brutia Species 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 235000006533 astragalus Nutrition 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 230000001143 conditioned effect Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 210000003200 peritoneal cavity Anatomy 0.000 description 3
- 210000003024 peritoneal macrophage Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000552 rheumatic effect Effects 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000001258 synovial membrane Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000045403 Astragalus propinquus Species 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- NGMYNFJANBHLKA-SENBMHEBSA-N Icariside II Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O)c(C/C=C(\C)/C)c3O2)cc1 NGMYNFJANBHLKA-SENBMHEBSA-N 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- -1 alkaloid compounds Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229930004069 diterpene Natural products 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 229960003699 evans blue Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- NGMYNFJANBHLKA-LVKFHIPRSA-N icariside II Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O)C(CC=C(C)C)=C2O1 NGMYNFJANBHLKA-LVKFHIPRSA-N 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000000518 rheometry Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 210000005222 synovial tissue Anatomy 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 241000227129 Aconitum Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000717682 Anisomeles Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 206010067632 Cartilage atrophy Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000134884 Ericales Species 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000421432 Glochidion Species 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100046526 Mus musculus Tnf gene Proteins 0.000 description 1
- 108010052989 Naphthol AS D Esterase Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 241000830536 Tripterygium wilfordii Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ZBZFFMBWUCAHIW-UHFFFAOYSA-L disodium propan-2-one sulfate Chemical compound [Na+].[Na+].CC(C)=O.[O-]S([O-])(=O)=O ZBZFFMBWUCAHIW-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002872 effect on rheumatism Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000033687 granuloma formation Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- MZWKCFGWAWRHDY-UHFFFAOYSA-N s-[2-(diethylamino)ethyl] 2,2-diphenylethanethioate;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C(=O)SCCN(CC)CC)C1=CC=CC=C1 MZWKCFGWAWRHDY-UHFFFAOYSA-N 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003848 thrombocyte activating factor antagonist Substances 0.000 description 1
- 235000015398 thunder god vine Nutrition 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
- 权 利 要 求1. 一种抗风湿药物, 其特征在于该药物由下述原料药制成:昆明山海棠 淫羊藿 枸杞子 菟丝子其中原料药可以是由昆明山海棠与其余三种药物中的任何一种或两 种或三种共同組成。
- 2. 如权利要求 1所述的药物, 其特征在于该药物由下述份量的原料 药制成:昆明山海棠 1 ~ 4重量份 淫羊藿 1 ~ 4重量份枸杞子 1 ~ 4重量份 菟丝子 1 ~ 4重量份
- 3. 如权利要求 1所述的药物, 其特征在于该药物由下述份量的原料 药制成:昆明山海棠 2重量份 淫羊藿 2重量份枸杞子 1重量份 菟丝子 1 重量份
- 4. 如权利要求 1所述的药物, 其特征在于还可以由上述原料药当中 的有效成分制备而成, 其中淫羊藿可以由淫羊藿甙, 淫羊藿次甙 I, 淫 羊藿次甙 Π和淫羊藿糖甙 A 中的一种或一种以上代替, 昆明山海棠可以 由昆明山海棠当中的 萜类,三萜类和生物碱类化合物代替, 菟丝子和枸 杞子可以由其中所含的黄酮代替。
- 5. 如权利要求 1、 2或 3所迷的药物的制备方法, 其特征在于该方法 包括下列步骤:称取原料药, 淫羊藿、 昆明山海棠分别切碎; 枸杞子、 菟丝子原形 或粉碎, 以上四味, 分别或合并用 0 ~ 95 %的乙醇于 10 ~ 98°C提取, 连 续 1 4次, 提取液分别或合并回收乙醇后浓缩, 干燥, 粉碎, 混匀或按 比例混匀, 制成临床可接受的剂型;或者称取原料药: 淫羊藿、 昆明山海棠切碎, 分别加水煎煮三次, 枸 杞子或菟丝子分别用 80°C ~ 95°C水温浸 1 ~ 3次, 每味中药的三次煎煮液 或温浸液分别合并后, 各合并液分别上各自对应的大孔吸附树脂柱。 吸附 完毕, 用水冲洗树脂柱至流出液澄清, 然后用 30 ~ 99. 5%乙醇洗脱, 至流 出液颜色变深时开始收集洗脱液, 直至洗脱液颜色由深变为很浅时, 用水 压出柱上乙醇液, 并与洗脱液合并, 总洗脱液用量约为药材重量的 1 8 倍;每味中药的洗脱液分别回收、 浓缩至比重 1. 10, 分別或合并喷雾干燥 得各药材提取物。 将各药材提取物按比例混匀, 制成临床可接受的剂型。
- 6. 如权利要求 1、 2或 3所述药物的制备方法, 其特征在于用该方法 可制成包括硬胶嚢、 软胶嚢、 片剂、 颗粒剂、 针剂在内的任何临床可接 受的剂型。
- 7. 如权利要求 1、 2或 3所述药物的制备方法, 其特征在于该方法包 括下列步驟:昆明山海棠, 切成碎块, 分别加 13、 10、 10倍水提取三次, 每次 1 小时; 淫羊藿, 切段, 分别加 15、 10、 10倍水提取三次, 每次 1小时; 枸杞子粉碎成粗料, 用 20倍水 80 'C ~ 95°C温浸 1小时; 菟丝子粉碎成粗 粉,用 31倍水 90°C温浸 1小时;四味药材的水煎煮液或水浸液分别滤过, 分别通过 WLD或 D1Q1或其它型号大孔吸附树脂柱, 然后用 70%乙醇洗脱, 当流出液颜色明显变深时开始收集洗脱液。 当洗脱液颜色变得极浅时洗 脱完毕;每味药材的洗脱液分别回收乙醇、 浓缩、 干燥, 最后得到提取物 药粉;将提取物药粉按比例混匀, 制成临床可接受的剂型。
- 8. 如权利要求 1、 2或 3所述药物在制备抗风湿性关节炎和类风湿性 关节炎的药物中的应用。
- 9. 如权利要求 1、 2或 3所述药物在制备治疗***性红斑狼疮的药物 中的应用。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2002/000246 WO2003086425A1 (fr) | 2002-04-09 | 2002-04-09 | Médicament contre les rhumatismes et procédé de production |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1622819A true CN1622819A (zh) | 2005-06-01 |
CN100502911C CN100502911C (zh) | 2009-06-24 |
Family
ID=29220566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB028286421A Expired - Lifetime CN100502911C (zh) | 2002-04-09 | 2002-04-09 | 一种抗风湿药物及其制备方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20050220906A1 (zh) |
EP (1) | EP1510217B1 (zh) |
JP (1) | JP4413013B2 (zh) |
KR (1) | KR100811873B1 (zh) |
CN (1) | CN100502911C (zh) |
AU (1) | AU2002254842B2 (zh) |
CA (1) | CA2481459C (zh) |
HK (1) | HK1074792A1 (zh) |
WO (1) | WO2003086425A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109187810A (zh) * | 2018-10-29 | 2019-01-11 | 广州白云山陈李济药厂有限公司 | 一种治疗类风湿性关节炎中药组合物的检测方法 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100803577B1 (ko) * | 2005-11-30 | 2008-02-15 | (주)아모레퍼시픽 | 이카린의 가수분해물을 함유하는 화장료용 조성물 |
US20070259058A1 (en) * | 2006-05-04 | 2007-11-08 | Rulin Xiu | Morinda herbal extracts and compositions thereof |
KR20080025960A (ko) * | 2006-09-19 | 2008-03-24 | (주)아모레퍼시픽 | 이카리시드 ⅰⅰ의 제조 방법 및 이를 함유하는 미백용조성물 |
KR100821683B1 (ko) * | 2006-11-01 | 2008-04-15 | 우석대학교 산학협력단 | 이카리사이드 Ⅱ (icariside Ⅱ)를 유효성분으로 하는 혈관 형성 장애 관련 질환의 예방 및 치료용 조성물 |
CN101843629B (zh) * | 2010-06-11 | 2012-03-14 | 首都医科大学宣武医院 | 淫羊藿苷和含有淫羊藿苷的淫羊藿黄酮的新用途 |
CN102526387B (zh) * | 2012-02-27 | 2014-01-15 | 天津中医药大学 | 一种治疗早期糖尿病足的药物组合物及制备方法 |
WO2015024512A1 (zh) * | 2013-08-23 | 2015-02-26 | 北京珅奥基医药科技有限公司 | 阿可拉定在制备用于治疗flt-3有关疾病的药物中的用途 |
CN108272906A (zh) * | 2018-02-08 | 2018-07-13 | 珠海宝石康科技有限公司 | 一种火陨石酒及其制备方法 |
CN112138134B (zh) * | 2020-10-23 | 2021-10-22 | 国康堂(北京)文化传播有限公司 | 一种治疗妇科病的分周期中药敷贴及其制备方法 |
CN112899217A (zh) * | 2021-01-29 | 2021-06-04 | 江西中医药大学 | 含药肝孵育液药理法及麻杏石甘汤含药肝孵育液制备方法 |
CN115501242B (zh) * | 2022-11-07 | 2023-06-09 | 新乡医学院 | 箭藿苷a在制备治疗炎症性疾病的药物中的应用 |
CN116850221B (zh) * | 2023-07-20 | 2024-06-11 | 山东省科学院菏泽分院 | 一种牡丹雄蕊菟丝子复合物及其制备方法和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1088801A (zh) * | 1993-01-01 | 1994-07-06 | 中国人民解放军第一军医大学 | 治疗顽痹、特别是ra和as的中成药金关片及其制法 |
CN1058879C (zh) | 1996-06-26 | 2000-11-29 | 内蒙古阿拉善苁蓉集团有限责任总公司 | 一种苁蓉酒 |
CN1085085C (zh) | 1997-08-28 | 2002-05-22 | 徐瑞新 | 一种治疗风湿病的中药及其制作工艺 |
CN1207009C (zh) * | 2000-10-09 | 2005-06-22 | 四川省中药研究所 | 一种抗风湿药物及其制备方法 |
-
2002
- 2002-04-09 AU AU2002254842A patent/AU2002254842B2/en not_active Expired
- 2002-04-09 WO PCT/CN2002/000246 patent/WO2003086425A1/zh active Application Filing
- 2002-04-09 EP EP02724085.2A patent/EP1510217B1/en not_active Expired - Lifetime
- 2002-04-09 CA CA002481459A patent/CA2481459C/en not_active Expired - Lifetime
- 2002-04-09 CN CNB028286421A patent/CN100502911C/zh not_active Expired - Lifetime
- 2002-04-09 KR KR1020047016140A patent/KR100811873B1/ko active IP Right Grant
- 2002-04-09 JP JP2003583444A patent/JP4413013B2/ja not_active Expired - Lifetime
- 2002-04-09 US US10/510,617 patent/US20050220906A1/en not_active Abandoned
-
2005
- 2005-08-17 HK HK05107161.3A patent/HK1074792A1/xx not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109187810A (zh) * | 2018-10-29 | 2019-01-11 | 广州白云山陈李济药厂有限公司 | 一种治疗类风湿性关节炎中药组合物的检测方法 |
CN109187810B (zh) * | 2018-10-29 | 2021-06-08 | 广州白云山陈李济药厂有限公司 | 一种治疗类风湿性关节炎中药组合物的检测方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2003086425A1 (fr) | 2003-10-23 |
EP1510217A1 (en) | 2005-03-02 |
JP4413013B2 (ja) | 2010-02-10 |
CA2481459C (en) | 2009-12-15 |
HK1074792A1 (en) | 2005-11-25 |
CN100502911C (zh) | 2009-06-24 |
US20050220906A1 (en) | 2005-10-06 |
EP1510217A4 (en) | 2007-08-01 |
JP2005530727A (ja) | 2005-10-13 |
CA2481459A1 (en) | 2003-10-23 |
KR20040101427A (ko) | 2004-12-02 |
EP1510217B1 (en) | 2015-11-11 |
AU2002254842A1 (en) | 2003-10-27 |
AU2002254842B2 (en) | 2008-05-29 |
KR100811873B1 (ko) | 2008-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100488552C (zh) | 一种治疗关节炎或痛风的中药组合物及其制备方法 | |
CN1622819A (zh) | 一种抗风湿药物及其制备方法 | |
CN105381334A (zh) | 一种治疗脂肪肝的中药组合物、制剂及制备方法 | |
CN103479963A (zh) | 一种治疗类风湿关节炎的中药胶囊及其制备方法 | |
US8003139B2 (en) | Pharmaceutical composition for treating rheumatism, and method of making same | |
CN103386022A (zh) | 一种治疗结核性胸膜炎的中药组合物 | |
CN115337356A (zh) | 一种治疗类风湿关节炎的药物组合物及其制备方法 | |
CN103417630B (zh) | 山鸡椒根提取物及其用途 | |
CN106177432A (zh) | 一种包含青钱柳叶、桑叶、绿茶和玉竹的保健组合物 | |
KR20180101460A (ko) | 근육의 보호에서 시스탄케 투불로사 추출물 및 이소악테오사이드의 용도 | |
CN101342249B (zh) | 一种***的中药制剂及其制备方法 | |
CN100534493C (zh) | 一种新的抗肿瘤复方药物 | |
CN109248188A (zh) | 一种金雀根提取物的制备方法及其应用 | |
CN101011543B (zh) | 一种新的抗肿瘤药物组合物 | |
CN108514568A (zh) | 苍耳子中噻嗪类化合物的制备方法及其医药用途 | |
CN100482266C (zh) | 一种由肿节风和白花蛇舌草制成的药物组合物 | |
KR100315001B1 (ko) | 장생도라지추출물을포함하는당뇨병치료용한방제제 | |
CN113952419A (zh) | 一种用于慢性肾功能衰竭的药物组合物及制备方法和应用 | |
CN101474315B (zh) | 一种祖师麻的有效组分群及其制备方法和应用 | |
CN111991519A (zh) | 一种治疗慢阻肺的藏药组合物及其制备方法 | |
CN104998085A (zh) | 一种可增强免疫功能的中药复方组合物及其制备方法 | |
CN101269152A (zh) | 枸杞子和黑木耳在制备抗脂肪肝药物中的应用 | |
CN113499359B (zh) | 一种治疗肾病的组合物、颗粒剂及制备方法 | |
CN110215474B (zh) | 一种活血化瘀中药组合物及其应用 | |
CN109303790B (zh) | 刺山柑或刺山柑提取物的医药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1074792 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1074792 Country of ref document: HK |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 610041 No. four, South Renmin Road, Sichuan, Chengdu province 51 Patentee after: Sichuan Traditional Chinese Medicine Institute Patentee after: GUANGZHOU CHENLIJI PHARMACEUTICAL FACTORY Address before: 610041 No. four, South Renmin Road, Sichuan, Chengdu province 51 Patentee before: Sichuan Traditional Chinese Medicine Institute Patentee before: Guangzhou Chenliji Pharmaceutical Factory |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20090624 |